Early Prediction of Postpartum Glucose Metabolism Abnormalities in Gestational Diabetes Mellitus
Early Prediction of Postpartum Glucose Metabolism Abnormalities in Gestational Diabetes Mellitus Based on Gestational Metabolic Profile and Lipid Profile
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Zhaoxia Liang, Prof.
- Phone Number: 86571-89992115
- Email: xiaozaizai@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310006
- Recruiting
- Women's Hospital School Of Medicine Zhejiang University
-
Contact:
- Zhaoxia Liang, Prof.
- Phone Number: 86571-89992115
- Email: xiaozaizai@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Plan to have routine prenatal examinations and give birth in the research center
- GDM was diagnosed at 24-28 gestational weeks
- Singleton pregnancy
- Without other pregnancy complications
- Willing to cooperate with the hospital to follow up
Exclusion Criteria:
- Have diseases that affect metabolic function or even threaten the life of the mother and fetus before pregnancy, such as diabetes, heart disease, liver and kidney diseases, thyroid diseases with drug, autoimmune diseases, malignant tumors, AIDS, etc.
- Fetus has a known deformity or genetic defects
- Incomplete clinical data
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Abnormal postpartum glucose metabolism
GDM with positive OGTT results at 6-12 weeks postpartum
|
A questionnaire survey was conducted when pregnant women were enrolled, and blood were collected at 24-28 gestational weeks.
Placenta and umbilical cord blood are collected during delivery.
|
|
Control
GDM with negative OGTT results at 6-12 weeks postpartum
|
A questionnaire survey was conducted when pregnant women were enrolled, and blood were collected at 24-28 gestational weeks.
Placenta and umbilical cord blood are collected during delivery.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum lipidomics
Time Frame: During the 24-28 geatational weeks.
|
The differential serum lipid molecules in serum were detected by the self-developed detection chip, and the markers related to postpartum glucose metabolism abnormalities in GDM were screened.
Specimens were collected during the 24-28 geatational weeks.
|
During the 24-28 geatational weeks.
|
|
Serum metabolomics
Time Frame: During the 24-28 geatational weeks.
|
The differential serum metabolism molecules in serum were detected by the self-developed detection chip, and the markers related to postpartum glucose metabolism abnormalities in GDM were screened.
Specimens were collected during the 24-28 geatational weeks.
|
During the 24-28 geatational weeks.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Zhaoxia Liang, Prof., Women's Hospital School Of Medicine Zhejiang University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB-20220336-R
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.